Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.78 USD | -1.08% | -4.65% | -14.76% |
03/05 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
02/05 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.76% | 3.42B | |
+3.71% | 108B | |
+11.00% | 104B | |
+1.28% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.42% | 17.64B | |
+3.89% | 14.05B | |
+36.64% | 12.51B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Wedbush Cuts Price Target on Ultragenyx Pharmaceutical to $43 From $47, Maintains Neutral Rating